Business / Finance

RSS

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

19 Sep 2013

Inovalon, Walgreens sign agreement to bring innovative solutions to healthcare marketplace

Inovalon, Inc., a leading provider of data-driven healthcare solutions, and Walgreens, the nation's largest drugstore chain, today announced that they have entered into a multi-year agreement to provide Inovalon's data-driven encounter support platform, Electronic Patient Assessment Solution Suite within Healthcare Clinic at select Walgreens to support improvements in managed care quality and performance.

19 Sep 2013

Gentiva, Harden enter into definitive merger agreement

Gentiva Health Services, Inc., the largest provider of home health and hospice services in the United States based on revenue, and Harden Healthcare Holdings, Inc., a leading provider of home health, hospice and community care services, announced today that they have entered into a definitive merger agreement whereby Gentiva will acquire Harden.

19 Sep 2013

Ventana, Boehringer Ingelheim to develop companion diagnostic tests for oncology programs

Ventana Medical Systems, Inc., a member of the Roche Group, and Boehringer Ingelheim announced today that they have entered into an agreement to collaborate on the development of companion diagnostic tests for Boehringer Ingelheim oncology programs.

19 Sep 2013

CTI completes sale of 15,000 shares to Quogue Capital

Cell Therapeutics, Inc. today announced the closing of its previously announced sale of 15,000 shares of its Series 18 Preferred Stock directly to Quogue Capital LLC and an affiliate of Perceptive Advisors LLC in a registered direct offering conducted without an underwriter or placement agent for gross proceeds of approximately $15 million (the "Offering").

19 Sep 2013

Mitsubishi Tanabe Pharma acquires Medicago

Mitsubishi Tanabe Pharma Corporation and Medicago Inc. announced today the completion of the previously announced acquisition of Medicago Inc. by MTPC.

18 Sep 2013

Dendreon Gets Green Light In Europe

...

17 Sep 2013

BMS Licenses Peptidream Technology, Extends Collaboration

...

17 Sep 2013

Biocryst Wins Potentially $22M NIAID Contract To Develop Marburg Virus Disease Drug

...

17 Sep 2013

LSO Medical, GME German Medical Engineering form strategic partnership

LSO Medical SAS, a leading French laser manufacturer for aesthetic and surgical applications, and GME German Medical Engineering GmbH, a German company developing and marketing laser applications, announced today the formation of a strategic partnership.

17 Sep 2013

Neostem Licenses UCSF Patents Covering Methods For "Tregs"

...

16 Sep 2013

Bruker Launches Second Phase Of SISCAPA-MALDI Collaboration

After focusing on confirming the utility and quantitative precision of the SISCAPA-MALDI workflow in the collaboration's first phase, Bruker said it plans to establish fully automated SISCAPA-MALDI capabilities in its demonstration facilities.

16 Sep 2013

Bangkok Hospital Group selects Elsevier's ClinicalKey to support clinical decision-making

Elsevier's flagship 'clinical insight engine' provides fast, comprehensive and trusted medical content and answers to more than 500 clinicians.

16 Sep 2013

MJFF Forms Research Tool Development Consortium For Parkinson's

...

13 Sep 2013

Prairie Technologies acquired by Bruker

Bruker Corporation today announced that it has acquired Prairie Technologies, Inc. (Prairie), a provider of life science fluorescence microscopy products. The acquisition strengthens Bruker’s position in life science markets, adding to the Bruker Nano Surfaces Division’s existing life science atomic force microscopy (Bio-AFM) systems.

From Bruker Nano Surfaces and Metrology 13 Sep 2013

Cell Therapeutics agrees to sell 15,000 shares of Series 18 Preferred Stock to Quogue Capital

Cell Therapeutics, Inc. today announced that it has agreed to sell 15,000 shares of its Series 18 Preferred Stock directly to Quogue Capital LLC and an affiliate of Perceptive Advisors LLC in a registered direct offering conducted without an underwriter or placement agent for gross proceeds of approximately $15 million (the "Offering").

13 Sep 2013